

1 **In Vitro Activities of Daptomycin Combined with Fosfomycin or Rifampin on**
2 **Planktonic and Adherent Linezolid-resistant *Enterococcus faecalis***

3 Jin-xin Zheng^{#1,2}, Xiang Sun^{#1}, Zhi-wei Lin^{#1}, Guo-bin Qi^{#2}, Hao-peng Tu¹, Yang Wu²,
4 Si-bo Jiang³, Zhong Chen^{1,2}, Qi-wen Deng¹, Di Qu^{*2}, Zhi-jian Yu^{*1}

5

6 ¹Department of Infectious Diseases and the Key Lab of Endogenous Infection,
7 Shenzhen Nanshan People's Hospital and The 6th Affiliated Hospital of Shenzhen
8 University Health Science Center, Shenzhen 518052, China.

9 ²Key Laboratory of Medical Molecular Virology of Ministries of Education and
10 Health, School of Basic Medical Science and Institutes of Biomedical Sciences,
11 Shanghai Medical College of Fudan University, Shanghai 200032, China.

12 ³Department of Pharmaceutics, University of Florida, Orlando 32827, USA

13

14 # Jin-xin Zheng, Xiang Sun, Zhi-wei Lin and Guo-bin Qi contributed equally to this
15 paper.

16 ***Corresponding author:** Di Qu: telephone: (+86)021-54237568, fax:

17 (+86)021-54237568, e-mail: dqu@fudan.edu.cn;

18 Zhi-jian Yu: telephone: (+86)0755-26553111, fax: (+86) 0755-26553111, e-mail:

19 yuzhijiansmu@163.com;

20

21 **Running title:** Daptomycin and fosfomycin against *E. faecalis* biofilms

22

23

24

25

26

27

28

29

30

31 **Abstract**

32 This study aimed to explore daptomycin combined with fosfomycin or rifampin
33 against the planktonic and adherent linezolid-resistant isolates of *Enterococcus*
34 *faecalis*. Four linezolid-resistant isolates of *E. faecalis* which formed biofilms were
35 collected for this study. Biofilm biomasses were detected by crystal violet staining.
36 The adherent cells in the mature biofilms were counted by CFU numbers and
37 observed by confocal laser scanning microscope (CLSM). In time-killing studies,
38 daptomycin combined with fosfomycin or rifampin (4xMIC) demonstrated
39 bactericidal activities on the planktonic cells, and daptomycin combined with
40 fosfomycin killed more planktonic cells (at least 2- \log_{10} CFU/ml) than daptomycin or
41 fosfomycin alone. Daptomycin alone showed activities against the mature biofilms,
42 and daptomycin combined with fosfomycin (16xMIC) demonstrated significantly
43 more activity than daptomycin or fosfomycin alone against the mature biofilms in
44 three of the four isolates. Daptomycin alone effectively killed the adherent cells, and
45 daptomycin combined with fosfomycin (16xMIC) killed more adherent cells than
46 daptomycin or fosfomycin alone in these mature biofilms. The high concentrations of
47 daptomycin (512 mg/L) combined with fosfomycin indicated more activity than
48 16xMIC of daptomycin combined with fosfomycin on the adherent cells and the
49 mature biofilms. The addition of rifampin increased the activity of daptomycin against
50 the biofilms and the adherent cells of FB-14 and FB-80 isolates, but was not observed
51 in FB-1 and FB-2 isolates. In conclusion, daptomycin combined with fosfomycin
52 works effectively against the planktonic and adherent linezolid-resistant isolates of *E.*
53 *faecalis*. The role of rifampin in these linezolid-resistant isolates is discrepant and
54 needs more studies.

55

56 **KEYWORDS:** *Enterococcus faecalis*; linezolid-resistant; biofilm; daptomycin;
57 fosfomycin; rifampin;

58

59 *Enterococcus faecalis* has become one of the most common pathogens of
60 nosocomial infections in the last two decades, which usually causes urinary tract,
61 respiratory tract, peritoneum, and bloodstream infections (1). Of particular concern is
62 the increasing difficult treatment of *E. faecalis* as it has intrinsic and acquired
63 resistance to many antimicrobial agents. The outbreaks of vancomycin-resistant
64 enterococci (VRE) infections attracted global attention due to their extensive
65 resistance to a plethora of antibiotics in recent years (2). Linezolid, was the first
66 antimicrobial agent of the oxazolidinones drugs to treat VRE infections, but the
67 growing cases of linezolid-resistant enterococci have emerged in hospitals with its
68 wide use (3).

69 In addition to the drug resistance problem, *E. faecalis* has been found with a high
70 capacity for biofilm formation, which makes infections more difficulty to treat. In
71 Britain, 100% of *E. faecalis* strains from bloodstream infections had the ability to
72 form biofilms, and another study from Japan indicated that all of 352 *E. faecalis*
73 isolates in urinary tract infections formed biofilms (4, 5). Other studies also showed
74 that about 50-90% of *E. faecalis* clinical isolates formed biofilms (6-8). Recently,
75 among 265 *E. faecalis* strains from China, 90% of linezolid-resistant isolates were
76 found with different levels of biofilm formation (9).

77 Biofilms are enclosed within an exopolymer matrix that can restrict the diffusion
78 and penetration of antimicrobials, and thus make them very difficult to erase (10). At
79 present, only a few antimicrobials showed activities on enterococci biofilms. Previous
80 research found that the daptomycin has more activity than linezolid against
81 biofilm-forming *E. faecalis*, and the addition of gentamicin to daptomycin
82 significantly improved bactericidal activity. However, the addition of rifampin
83 decreased the activity of daptomycin against both *E. faecalis* and VRE (11). Another
84 study indicated that the fosfomycin had activity against planktonic and adherent *E.*
85 *faecalis*, and found the rifampin had no activity on planktonic or adherent *E. faecalis*
86 (12). However, Tang HJ *et al.* found that a synergistic effect was evident using
87 fosfomycin plus rifampin on planktonic and adherent *E. faecalis* (13). So the effective
88 antimicrobials which work against *E. faecalis* biofilms are still little known and

89 controversial, and there are no reports about how to treat the linezolid-resistant *E.*
90 *faecalis* biofilms up to now. Thus, this study aims to explore the daptomycin, rifampin,
91 fosfomycin alone, and daptomycin combined with rifampin or fosfomycin against the
92 linezolid-resistant *E. faecalis* biofilms.

93

94 MATERIALS AND METHODS

95 **Bacterial strains.** From January 2014 to December 2016, ten linezolid-resistant *E. faecalis*
96 isolates were collected from inpatients at 6th Affiliated Hospital of Shenzhen University Health
97 Science Center in China. Among these linezolid-resistant isolates, four strains (FB-1, FB-2, FB-14,
98 FB-80) which formed biofilms were used for all in vitro experiments. The strains were identified
99 with a Phoenix 100 automated microbiology system (BD, Franklin Lakes, NJ, USA) and then two
100 subcultured generations were re-identified with matrix-assisted laser desorption ionization
101 time-of-flight mass spectrometry (IVD MALDI Biotyper, Germany). *E. faecalis* ATCC 29212 and
102 OG1RF (ATCC47077) were used as reference strains. All procedures involving human
103 participants were performed in accordance with the ethical standards of Shenzhen University and
104 with the 1964 Helsinki declaration and its later amendments. For this type of study, formal consent
105 is not required.

106 **Antimicrobial agents.** Ampicillin (catalogue no. A9518), Vancomycin (catalogue no.
107 V2002), Linezolid (catalogue no. PZ0014), Daptomycin (catalogue no. SBR00014), Rifampin
108 (catalogue no.R3501), Gentamicin (catalogue no. E003632) and glucose-6-phosphate (catalogue
109 no. V900924) were purchased from SIGMA-ALDRICH (Shanghai, China). Fosfomycin
110 (catalogue no. HY-B1075) was purchased from MedChemExpress (Shanghai, China). The media
111 were supplemented with 25 mg/liter glucose-6-phosphate for testing of fosfomycin and with 50
112 mg/liter Ca²⁺ for testing of daptomycin in all vitro experiments.

113 **Antimicrobial susceptibility testing.** The MICs and the logarithmic MBC (MBC_{log}) values
114 for ampicillin, vancomycin, linezolid, daptomycin, rifampin and gentamicin were determined by
115 the broth macrodilution method in cation-adjusted Mueller-Hinton broth (CAMHB), and the MICs
116 values for fosfomycin were detected by the agar dilution method according to the Clinical and
117 Laboratory Standards Institute guidelines (CLSI-M100-S26). All experiments were performed in
118 triplicate. The sensitivity results of antimicrobial agents were confirmed based on

119 CLSI-M100-S26.

120 **Time-killing assay.** The activities of daptomycin, rifampin, fosfomycin alone, and
121 daptomycin combined with rifampin or fosfomycin (4xMIC) were determined by time-kill studies
122 conducted with cells in the logarithmic growth phase based on the reference method (12). Briefly,
123 the tests were performed in 14ml Polypropylene Round-Bottom Tube (FALCON 352059) in a
124 final volume of 5 ml CAMHB and were further incubated at 37°C with shaking. At the time points
125 of 6, 12, and 24 h, 1-ml aliquots were sampled and washed with 0.9% saline solution. Ten-fold
126 dilutions were then plated on Muller-Hinton agar, and the numbers of CFU were determined.
127 Medium without antimicrobial agents was used as the growth control. Bactericidal activity was
128 defined as a $\geq 99.9\%$ (i.e., $\geq 3\text{-log}_{10}$ CFU/ml) reduction of the initial bacterial count after 24 h, and
129 the initial inoculum was $1.0\sim 3.0 \times 10^7$ CFU/ml. All experiments were performed in triplicate.

130 **Biofilm biomass assay.** Biofilm biomasses of *E. faecalis* isolates were detected according to
131 the reference method with minor modifications (8). Briefly, the *E. faecalis* isolates were cultivated
132 overnight in Tryptic Soy Broth (TSB) at 37°C. Overnight cultures were diluted 1:200 in 200 μ l of
133 TSBG (TSB with 0.25% glucose) ($1.0 - 3.0 \times 10^7$ CFU/ml) and inoculated into 96 polystyrene
134 microtiter plates (Costar3599, Corning). After 24 h of static incubation at 37°C (mature biofilm),
135 the supernatant was discarded and plates were washed thrice with 0.9% saline to remove
136 unattached cells, then the fresh TSBG containing antimicrobial agents was added to each well
137 (200 μ l/well), and the TSBG without antimicrobials was used as the growth control. After 72h of
138 static incubation at 37°C (the medium replaced daily), the supernatant was discarded and plates
139 were washed thrice with deionized water to remove unattached cells, stained with 1% crystal
140 violet (CV) for 20 min at room temperature and rinsed with distilled water. Last, the CV was
141 solubilized in ethanol-acetone (80:20, vol/vol), and optical density at 570 nm (OD_{570}) was
142 determined. The OG1RF (ATCC47077) strain was used as biofilm positive control. Each assay
143 was performed in triplicate at least three times.

144 **Bacteria counting in biofilm assay.** Bacteria in *E. faecalis* biofilms were determined
145 according to the reference method (14). The *E. faecalis* isolates overnight cultures were 1:200
146 diluted with TSBG and inoculated into 24 polystyrene microtiter plates (1ml/well; Costar3524,
147 Corning). After 24 h of static incubation at 37°C (mature biofilm), the supernatant was discarded
148 and plates were washed thrice with 0.9% saline, then the fresh TSBG containing antimicrobial

149 agents was added to each well (1ml/well), and the TSBG without antimicrobials was used as the
150 growth control. After 72h of static incubation at 37°C (the medium replaced daily), the
151 supernatant was discarded and plates were washed thrice with 0.9% saline, then the bacteria in the
152 biofilms were collected by scratching the wall of the wells with a flat end toothpick and suspended
153 in 0.9% saline. The bacteria suspension was washed twice with 0.9% saline, ten-fold diluted and
154 then plated on Tryptic Soy agar, and the numbers of CFU were determined. All experiments were
155 performed in triplicate.

156 **Detection of cell viability in mature biofilms by confocal laser scanning microscope**
157 **(CLSM).** The effect of antimicrobial agents on cell viability in mature biofilms was determined
158 using the Live/Dead Bacterial Viability method (Live/Dead BacLight, Molecular Probes, USA).
159 The *E. faecalis* isolates overnight cultures were 1:200 diluted with TSBG and inoculated into
160 cell-culture dishes (2ml/well; WPI, USA). After 24 h of static incubation at 37°C (mature biofilm),
161 the supernatant was discarded and plates were washed thrice with 0.9% saline, then the fresh
162 TSBG containing antimicrobial agents was added to each well (2ml/well), and the TSBG without
163 antimicrobials was used as the growth control. After 72h of static incubation at 37°C (the medium
164 replaced daily), the supernatant was discarded and plates were washed thrice with 0.9% saline.
165 Then the mature biofilms were stained with SYTO 9 and propidium iodide (PI) at room
166 temperature for 15 min, then observed under a Leica TCS SP8 CLSM with a 63 × 1.4-NA
167 oil-immersion objective. Further, image analysis was performed using IMARIS 7.0.0 software
168 (Bitplane) and the fluorescence quantities of biofilm were determined using Leica LAS AF Lite
169 4.0 software. All experiments were performed in triplicate and representative images were shown.

170 **Statistical analysis.** The data were analysed using Student's t test or nonparametric
171 Mann–Whitney U test. *P* values <0.05 were regarded as statistically significant. All data was
172 analyzed in SPSS software package (version 16.0, Chicago, IL,USA).

173

174 **RESULTS**

175 **Antimicrobial susceptibility.** The in vitro susceptibilities of planktonic *E.*
176 *faecalis* cells were summarized in **Table 1**. All the four *E. faecalis* isolates were
177 sensitive to ampicillin and vancomycin, but resistant to linezolid. Among these four *E.*
178 *faecalis* isolates, three isolates were sensitive to daptomycin and fosfomycin, but the

179 MIC of daptomycin to one isolate (FB-14) has reached to 8 mg/L and one isolate
180 (FB-2) has intermediate resistance to fosfomicin. Three isolates with low level
181 resistant to rifampin, and three isolates with the high level gentamicin MICs (≥ 512
182 mg/L) in this study.

183 **Antimicrobial activity on planktonic *E. faecalis* cells.** The activities of
184 daptomycin, rifampin, fosfomicin (all with 4xMIC) on planktonic *E. faecalis* cells
185 were determined by time-killing studies. Daptomycin combined with fosfomicin or
186 rifampin demonstrated bactericidal activities, and the daptomycin combined with
187 fosfomicin showed better bactericidal effect than combined with rifampin on FB-1
188 and FB-2 isolates (**Fig. 1A and B**). Daptomycin alone, or combined with rifampin or
189 fosfomicin indicated bactericidal activities, and daptomycin combined with
190 fosfomicin showed best bactericidal effect on FB-14 and FB-80 isolates. Among all
191 the four isolates, daptomycin combined with fosfomicin killed more planktonic *E.*
192 *faecalis* cells (at least 2- \log_{10} CFU/ml) than daptomycin or fosfomicin alone at the
193 24h of the time-kill study. It was noteworthy that rifampin or fosfomicin alone
194 inhibited the growth of planktonic *E. faecalis* cells before 6h, but the number of
195 bacteria increased after 6h or 12h of incubation in these four isolates (**Fig. 1**).

196 **Antimicrobial activity on the mature biofilms of *E. faecalis*.** First, the
197 activities of daptomycin, rifampin, fosfomicin (all with 16xMIC) on the mature
198 biofilms of these four linezolid-resistant isolates were explored by microplate method
199 with crystal violet staining. The median OD₅₇₀ value was 1.45 for OG1RF (biofilm
200 positive control strain). The daptomycin alone showed activities on the mature
201 biofilms of FB-2, FB-14 and FB-80 isolates, and rifampin alone exhibited activity
202 against the mature biofilms of FB-14 and FB-80 isolates (**Fig. 2**). Interestingly,
203 daptomycin combined with fosfomicin demonstrated significantly more activity than
204 daptomycin or fosfomicin alone against the mature biofilms of FB-2, FB-14 and
205 FB-80 isolates. The addition of rifampin increased the activity of daptomycin against
206 the biofilms of FB-14 and FB-80 isolates. However, daptomycin, rifampin and
207 fosfomicin (all with 16xMIC) had no effect on the mature biofilm of FB-1 (**Fig. 2A**).
208 Subsequently, we increased the concentrations of daptomycin from 16xMIC to 512

209 mg/L, and found that the high concentrations of daptomycin (512 mg/L) combined
210 with fosfomycin also indicated good effect on the mature biofilm of FB-1 (**Fig. 3A**).
211 Additionally, the high concentrations of daptomycin (512 mg/L) combined with
212 fosfomycin showed more activity than 16xMIC of daptomycin combined with
213 fosfomycin against the mature biofilms of these four linezolid-resistant isolates (**Fig.**
214 **3**).

215 **Antimicrobial agents killed the adherent cells in the mature biofilms of *E.***
216 ***faecalis*.** How daptomycin, rifampin, and fosfomycin killed the adherent cells in the
217 mature biofilms of *E. faecalis* were determined by the CFU numbers. First, the effects
218 of these three agents (all with 16xMIC) on the adherent cells in the mature biofilms
219 were detected and we found that daptomycin alone effectively killed the adherent
220 cells in these mature biofilms of the four linezolid-resistant isolates (**Fig. 4**).
221 Interestingly, we also found that daptomycin combined with fosfomycin killed more
222 adherent cells than daptomycin or fosfomycin alone in these mature biofilms. The
223 addition of rifampin also increased the activity of daptomycin against the adherent
224 cells in the mature biofilms of FB-14 and FB-80 isolates. When the concentrations of
225 daptomycin were increased from 16xMIC to 512 mg/L, we found that the high
226 concentrations of daptomycin (512 mg/L) combined with fosfomycin showed
227 significantly more killing activity than 16xMIC of daptomycin combined with
228 fosfomycin on the adherent cells in the mature biofilms of the four linezolid-resistant
229 isolates (**Fig. 5**).

230 **Effects of daptomycin and fosfomycin on the adherent cells in the mature**
231 **biofilms by CLSM.** The effects of daptomycin and fosfomycin on cell viability in
232 mature biofilms were detected by CLSM (rifampin was excepted as its red solution
233 influenced the propidium iodide, which stained the dead cells with red fluorescence).
234 As the **Fig. 6-9** indicated, daptomycin alone had effect on the adherent cells in these
235 mature biofilms of the four linezolid-resistant isolates. Similar to the above results,
236 daptomycin combined with fosfomycin showed stronger effect than daptomycin or
237 fosfomycin alone, and the high concentrations of daptomycin (512 mg/L) combined
238 with fosfomycin also indicated significantly stronger effect than 16xMIC of

239 daptomycin combined with fosfomycin on the adherent cells in the mature biofilms.

240

241 **DISCUSSION**

242 The combination of daptomycin and fosfomycin has been explored in different *E.*
243 *faecalis* isolates. In the later 1980s, the combination of daptomycin and fosfomycin
244 exhibited consistent synergistic bactericidal activity against *E. faecalis* isolates with
245 high-level gentamicin resistance Three isolates with low level resistant to rifampin
246 (15). Subsequently, fosfomycin was found to have synergy with daptomycin against
247 vancomycin-resistant isolates of *E. faecium* from renal transplant patients and was
248 also found to enhance the activity of daptomycin against vancomycin-resistant
249 isolates of *E. faecalis* (16, 17). However, another study indicated that fosfomycin had
250 no synergistic bactericidal effect with daptomycin on the planktonic and adherent *E.*
251 *faecalis* (ATCC19433) (18). In this study, the combination of daptomycin and
252 fosfomycin showed high bactericidal activity and a synergistic effect on the
253 planktonic and adherent linezolid-resistant isolates of *E. faecalis*. Our results were
254 similar with the high-level gentamicin resistant or vancomycin-resistant isolates of *E.*
255 *faecalis* (15-17), but different from the *E. faecalis* ATCC19433, which was sensitive
256 to vancomycin or linezolid (18). Why the combination of daptomycin and fosfomycin
257 has a different effect on the linezolid-sensitive and resistant isolates of *E. faecalis* is
258 still unknown and needs further exploration.

259 The high-dose daptomycin (10 mg/kg/day) plus fosfomycin has been proven to be
260 safe and effective in treating *S. aureus* endocarditis (19). Another study also found
261 that the high-dose daptomycin (≥ 8 mg/kg/day) was effective and safe for the
262 treatment of infective endocarditis, which is mostly caused by methicillin-resistant *S.*
263 *aureus* and vancomycin-resistant *E. faecium* (20). Similar to the above research, the
264 present study also showed that the high concentrations of daptomycin (512 mg/L)
265 combined with fosfomycin had a significantly stronger effect on the mature biofilms
266 and the adherent cells of the linezolid-resistant isolates than 16xMIC of daptomycin
267 combined with fosfomycin. Thus, the patients infected with linezolid-resistant *E.*
268 *faecalis* may also benefit from treatment with high-dose daptomycin, but this issue

269 needs further in vivo studies.

270 Fosfomycin has indicated activity against both Gram-positive and Gram-negative
271 biofilms, such as *pseudomonas aeruginosa*, *Escherichia coli* and *S. aureus* (21-23).
272 There are several studies that have reported fosfomycin is effective against *E. faecalis*
273 biofilms, but this is still controversial. Oliva A *et al* indicated that fosfomycin alone
274 cleared planktonic bacteria from 74% of cage fluids and eradicated biofilm bacteria
275 from 43% of cages in their study (12). However, another study found that among
276 vancomycin-resistant *E. faecalis* and *E. faecium* isolates, fosfomycin alone had no
277 bactericidal effect on the planktonic and adherent bacteria (13). Our study also
278 showed that fosfomycin alone had no significantly killing activity on the planktonic
279 and adherent cells among these linezolid-resistant isolates of *E. faecalis*. Thus, the
280 role of fosfomycin in *E. faecalis* biofilm infections has not been widely investigated
281 and needs further confirmation. In addition to the uncertainty of the effect of
282 fosfomycin alone on the biofilm-related infections, prolonged therapy with
283 fosfomycin may promote the emergence of fosfomycin-resistant isolates (24). So
284 fosfomycin is not recommended for monotherapy in clinical practice, and
285 fosfomycin-included combined treatment may provide better options in these
286 biofilm-related infections.

287 Rifampin alone or combined with linezolid or vancomycin achieved good effects
288 on the biofilms of methicillin-resistant *Staphylococcus aureus* (MRSA) strains, and
289 was even effective against the implant-associated infections which are caused by
290 MRSA (25-27). However, the role of rifampin in enterococcal infection remains
291 confusing and controversial. Rifampin was explored effectively against the biofilms
292 of vancomycin sensitive *E. faecalis* in combination with ciprofloxacin and linezolid in
293 vitro, and in combination with tigecycline in vivo studies (28, 29). Tang HJ *et al.* also
294 found that rifampin combined with fosfomycin indicated a synergistic effect on the
295 planktonic and adherent *E. faecalis* isolates, which are resistant to vancomycin (13).
296 In contrast to the above results, Oliva A *et al.* found rifampin with no activity against
297 enterococcal biofilms of *E. faecalis* ATCC19433 (sensitive to vancomycin), either in
298 vitro or in vivo (12). Another study showed the addition of rifampin even decreased

299 the activity of daptomycin against the biofilms of vancomycin-susceptible *E. faecalis*
300 (11). However, the present study found the addition of rifampin increased the activity
301 of daptomycin against the planktonic *E. faecalis* isolates, which are more obvious in
302 FB-2 and FB-14 strains. This study also found that rifampin increased the activity of
303 daptomycin on the adherent cells and mature biofilms among FB-14 and FB-80
304 isolates, but was not observed in FB-1 and FB-2 strains. Based on the previous and
305 present studies, rifampin indicated disparate effects on the different *E. faecalis*
306 isolates, and was not related to the antimicrobial susceptibility, such as vancomycin or
307 linezolid.

308 In conclusion, this study indicated that daptomycin combined with fosfomycin
309 works effectively against the planktonic and adherent linezolid-resistant isolates of *E.*
310 *faecalis*. The high concentrations of daptomycin combined with fosfomycin achieved
311 significantly stronger effect on these isolates. However, the role of rifampin in these
312 linezolid-resistant isolates of *E. faecalis* is inconsistent and needs more studies to
313 resolve this issue.

314

315 **ACKNOWLEDGMENTS**

316 The authors thank Prof. Xiao-gang Xu (Institute of Antibiotics, Huashan Hospital,
317 Fudan University, Shanghai, China) for his suggestions on the experiment schemes
318 and thank MS. Cynthia Brast (University of Florida, Orlando, USA) for her review
319 on this manuscript.

320

321 **FUNDING**

322 This work was supported by grants from the National Natural Science Foundation
323 of China (grant number 81170370); the Sanming Project of Medicine in Shenzhen
324 (grant number SMGC201705029); the Shenzhen Scientific Research Program (grant
325 numbers JCYJ20170412143551332, JCYJ20170307153714512,
326 JCYJ20170307153425389, JCYJ20170307153919735); the Scientific Research
327 Project of the Shenzhen Health and Family Planning System (grant number

328 201601058); and the Shenzhen Nanshan District Scientific Research Program of the
329 People's Republic of China (grant number 2016010).

330

331 **CONFLICT of INTEREST**

332 The authors declare that they have no conflicts of interest.

333

334 **REFERENCES**

- 335 1. Beganovic M, Luther MK, Rice LB, Arias CA, Rybak MJ, LaPlante KL. 2018. A Review of
336 Combination Antimicrobial Therapy for *Enterococcus Faecalis* Bloodstream Infections and
337 Infective Endocarditis. Clin Infect Dis. <https://doi: 10.1093/cid/ciy064>. [Epub ahead of print]
- 338 2. Flokas ME, Karageorgos SA, Detsis M, Alevizakos M, Mylonakis E. 2017.
339 Vancomycin-resistant enterococci colonisation, risk factors and risk for infection among
340 hospitalised paediatric patients: a systematic review and meta-analysis. Int J Antimicrob Agents
341 49: 565-572. <https://doi: 10.1016/j.ijantimicag.2017.01.008>.
- 342 3. Lazaris A, Coleman DC, Kearns AM, Pichon B, Kinnevey PM, Earls MR, *et al.* 2017. Novel
343 multiresistance cfr plasmids in linezolid-resistant methicillin-resistant *Staphylococcus*
344 *epidermidis* and vancomycin-resistant *Enterococcus faecium* (VRE) from a hospital outbreak:
345 co-location of cfr and optrA in VRE. J Antimicrob Chemother 72: 3252-3257. <https://doi: 10.1093/jac/dkx292>.
- 347 4. Sandoe J A, Witherden IR, Cove JH, Heritage J, Wilcox MH. 2003. Correlation between
348 enterococcal biofilm formation in vitro and medical-device-related infection potential in vivo.
349 J Med Microbiol 52: 547-550.
- 350 5. Seno Y, Kariyama R, Mitsuhata R, Monden K, Kumon H. 2005. Clinical implications of biofilm
351 formation by *Enterococcus faecalis* in the urinary tract. Acta Med Okayama 59: 79-87.
- 352 6. Toledo-Arana A, Valle J, Solano C, Arrizubieta M, Cucarella C, Lamata M, *et al.* 2001. The
353 enterococcal surface protein, Esp, is involved in *Enterococcus faecalis* biofilm formation. Appl
354 Environ Microbiol 67: 4538-4545.
- 355 7. Dupre I, Zanetti S, Schito AM, Fadda G, Sechi LA. 2003. Incidence of virulence determinants in
356 clinical *Enterococcus faecium* and *Enterococcus faecalis* isolates collected in Sardinia (Italy). J
357 Med Microbiol 52: 491-498.
- 358 8. Mohamed JA, Huang W, Nallapareddy SR, Teng F, Murray BE. 2004. Influence of origin of
359 isolates, specially endocarditis isolates, and various genes on biofilm formation by
360 *Enterococcus faecalis*. Infect Immun 72: 3658-3663.
- 361 9. Zheng JX, Wu Y, Lin ZW, Pu ZY, Yao WM, Chen Z, *et al.* 2017. Characteristics of and
362 Virulence Factors Associated with Biofilm Formation in Clinical *Enterococcus faecalis* Isolates
363 in China. Front Microbiol 8: 2338. <https://doi: 10.3389/fmicb.2017.02338>.
- 364 10. Lewis K. Riddle of biofilm resistance. 2001. Antimicrob Agents Chemother 45: 999-1007.
- 365 11. Luther MK, Arvanitis M, Mylonakis E, LaPlante KL. 2014. Activity of Daptomycin or
366 Linezolid in Combination with Rifampin or Gentamicin against Biofilm-Forming *Enterococcus*
367 *faecalis* or *E. faecium* in an In Vitro Pharmacodynamic Model Using Simulated Endocardial
368 Vegetations and an In Vivo Survival Assay Using *Galleria mellonella* Larvae. Antimicrob
369 Agents Chemother 58: 4612-4620. <https://doi: 10.1128/AAC.02790-13>.

- 370 **12.** Oliva A, Furustrand Tabin U, Maiolo EM, Jeddari S, Bétrisey B, Trampuz A. 2014. Activities
371 of Fosfomycin and Rifampin on Planktonic and Adherent *Enterococcus faecalis* Strains in an
372 Experimental Foreign-Body Infection Model. *Antimicrob Agents Chemother* 58: 1284-1293.
373 [https://doi: 10.1128/AAC.02583-12](https://doi.org/10.1128/AAC.02583-12).
- 374 **13.** Tang HJ, Chen CC, Zhang CC, Su BA, Li CM, Weng TC, *et al.* 2013. In vitro efficacy of
375 fosfomycin-based combinations against clinical vancomycin-resistant *Enterococcus* isolates.
376 *Diagn Microbiol Infect Dis* 77: 254-257. [https://doi: 10.1016/j.diagmicrobio.2013.07.012](https://doi.org/10.1016/j.diagmicrobio.2013.07.012).
- 377 **14.** Wang C, Li M, Dong D, Wang J, Ren J, Otto M, *et al.* 2007. Role of ClpP in biofilm formation
378 and virulence of *Staphylococcus epidermidis*. *Microbes Infect* 9: 1376-1383.
- 379 **15.** Rice LB, Eliopoulos GM, Moellering RC Jr. 1989. In Vitro Synergism between Daptomycin
380 and Fosfomycin against *Enterococcus faecalis* Isolates with High-Level Gentamicin
381 Resistance. *Antimicrob Agents Chemother* 33:470-473.
- 382 **16.** Descourouez JL, Jorgenson MR, Wergin JE, Rose WE. 2013. Fosfomycin Synergy In Vitro
383 with Amoxicillin, Daptomycin, and Linezolid against Vancomycin-Resistant *Enterococcus*
384 *faecium* from Renal Transplant Patients with Infected Urinary Stents. *Antimicrob Agents*
385 *Chemother* 57:1518-1520. [https://doi: 10.1128/AAC.02099-12](https://doi.org/10.1128/AAC.02099-12).
- 386 **17.** Hall Snyder AD, Werth BJ, Nonejuie P, McRoberts JP, Pogliano J, Sakoulas G, *et al.* 2016.
387 Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci
388 in an In Vitro Pharmacokinetic-Pharmacodynamic Model. *Antimicrob Agents Chemother*
389 60:5716-5723. [https://doi: 10.1128/AAC.00687-16](https://doi.org/10.1128/AAC.00687-16).
- 390 **18.** Oliva A, Furustrand Tabin U, Maiolo EM, Jeddari S, Bétrisey B, Trampuz A. 2014. Activities
391 of Fosfomycin and Rifampin on Planktonic and Adherent *Enterococcus faecalis* Strains in an
392 Experimental Foreign-Body Infection Model. *Antimicrob Agents Chemother* 58:1284-1293.
393 [https://doi: 10.1128/AAC.02583-12](https://doi.org/10.1128/AAC.02583-12).
- 394 **19.** Miró JM, Entenza JM, Del Río A, Velasco M, Castañeda X, Garcia de la Mària C, *et al.* 2012.
395 High-Dose Daptomycin plus Fosfomycin Is Safe and Effective in Treating
396 Methicillin-Susceptible and Methicillin-Resistant *Staphylococcus aureus* Endocarditis.
397 *Antimicrob Agents Chemother* 56: 4511-4515.
- 398 **20.** Kullar R, Casapao AM, Davis SL, Levine DP, Zhao JJ, Crank CW, *et al.* 2013. A multicentre
399 evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of
400 infective endocarditis. *J Antimicrob Chemother* 68: 2921-2926. [https://doi:](https://doi.org/10.1093/jac/dkt294)
401 [10.1093/jac/dkt294](https://doi.org/10.1093/jac/dkt294).
- 402 **21.** Mikuniya T, Kato Y, Ida T, Maebashi K, Monden K, Kariyama R, *et al.* 2007. Treatment of
403 *Pseudomonas aeruginosa* biofilms with a combination of fluoroquinolones and fosfomycin in
404 a rat urinary tract infection model. *J Infect Chemother* 13: 285-290.
- 405 **22.** Corvec S, Furustrand Tabin U, Bétrisey B, Borens O, Trampuz A. 2013. Activities of
406 fosfomycin, tigecycline, colistin, and gentamicin against extended-spectrum
407 lactamase-producing *Escherichia coli* in a foreignbody infection model. *Antimicrob Agents*
408 *Chemother* 57:1421-1427.
- 409 **23.** Garrigos C, Murillo O, Lora-Tamayo J, Verdaguer R, Tubau F, Cabellos C, *et al.* 2013.
410 Fosfomycin-daptomycin and other fosfomycin combinations as alternative therapies in
411 experimental foreign-body infection by methicillin-resistant *Staphylococcus aureus*. *Antimicrob*
412 *Agents Chemother* 57: 606-610. [https://doi: 10.1128/AAC.01570-12](https://doi.org/10.1128/AAC.01570-12).
- 413 **24.** Raz R. 2012. Fosfomycin: an old-new antibiotic. *Clin Microbiol Infect* 18: 4-7. [https://doi:](https://doi.org/10.1128/AAC.01570-12)

- 414 10.1111/j.1469-0691.2011.03636.x.
- 415 **25.** Zimmerli W, Widmer AF, Blatter M, Frei R, Ochsner PE. 1998. Role of rifampin for treatment
416 of orthopedic implant-related staphylococcal infections: a randomized controlled trial.
417 Foreign-Body Infection (FBI) Study Group. JAMA 279: 1537-1541.
- 418 **26.** Baldoni D, Haschke M, Rajacic Z, Zimmerli W, Trampuz A. 2009. Linezolid alone or
419 combined with rifampin against methicillin-resistant *Staphylococcus aureus* in experimental
420 foreign-body infection. Antimicrob Agents Chemother 53:1142-1148. [https://doi:](https://doi:10.1128/AAC.00775-08)
421 10.1128/AAC.00775-08.
- 422 **27.** Vergidis P, Rouse MS, Euba G, Karau MJ, Schmidt SM, Mandrekar JN, *et al.* 2011. Treatment
423 with linezolid or vancomycin in combination with rifampin is effective in an animal model of
424 methicillin-resistant *Staphylococcus aureus* foreign body osteomyelitis. Antimicrob Agents
425 Chemother 55:1182-1186. [https://doi: 10.1128/AAC.00740-10](https://doi:10.1128/AAC.00740-10).
- 426 **28.** Holmberg A, Morgelin M, Rasmussen M. 2012. Effectiveness of ciprofloxacin
427 or linezolid in combination with rifampicin against *Enterococcus faecalis* in biofilms. J
428 Antimicrob Chemother 67:433-439. [https://doi: 10.1093/jac/dkr477](https://doi:10.1093/jac/dkr477).
- 429 **29.** Minardi D, Cirioni O, Ghiselli R, Silvestri C, Mocchegiani F, Gabrielli
430 E, *et al.* 2012. Efficacy of tigecycline and rifampin alone and in combination against
431 *Enterococcus faecalis* biofilm infection in a rat model of ureteral stent. J Surg Res 176: 1-6.
432 [https://doi: 10.1016/j.jss.2011.05.002](https://doi:10.1016/j.jss.2011.05.002).

433

434

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451


452 **Table 1. Antimicrobial susceptibility of *E.faecalis* determined by conventional broth**
 453 **macrodilution or agar dilution method.**

Antimicrobial agents	Susceptibility (mg/L)							
	FB-1		FB-2		FB-14		FB-80	
	MIC	MBC _{log}	MIC	MBC _{log}	MIC	MBC _{log}	MIC	MBC _{log}
Ampicillin	1	32	1	64	2	64	2	32
Vancomycin	2	128	2	64	2	256	2	128
Linezolid	16	>512	16	>512	32	>512	16	>512
Daptomycin	4	64	4	64	8	128	4	64
Rifampin	4	512	4	256	4	512	0.5	64
Fosfomycin ^a	64	-	128	-	64	-	64	-
Gentamicin	>512	>512	>512	>512	16	64	512	>512

454 Note: MIC, minimum inhibitory concentration; MBC_{log}, the MBC during the logarithmic growth
 455 phase; ^aMIC of Fosfomycin: agar dilution method;


456

457



458

459 **Figure. 1 Time-kill studies for FB-1 (A), FB-2 (B), FB-14 (C), and FB-80 (D) during**
 460 **logarithmic growth.** The horizontal dashed line represents the reduction of 3 log₁₀ CFU/ml
 461 compared to the initial bacterial count. DAP, daptomycin; RIF, rifampin; FOS, fosfomycin. All
 462 the three agents were used at 4xMIC.



463

464 **Figure. 2 Antimicrobial activity on the mature biofilms of FB-1 (A), FB-2 (B), FB-14 (C), and**

465 **FB-80 (D).** The biofilm biomass of *E. faecalis* was determined by microplate method with crystal


466 violet. DAP, daptomycin; RIF, rifampin; FOS, fosfomycin. All the three agents were used at

467 16xMIC. *: DAP vs Control, P<0.05; **: RIF vs Control, P<0.05; ***: DAP+FOS vs DAP or

468 FOS alone, P<0.05.

469

470




471
472 **Figure. 3 Antimicrobial activity of daptomycin combined with fosfomycin on the mature**
473 **biofilms of FB-1 (A), FB-2 (B), FB-14 (C), and FB-80 (D).** DAP, daptomycin, 64 (16xMIC),
474 128 (32xMIC), 256 (64xMIC), 512 (128xMIC) mg/L were used for FB-1, FB-2, FB-80, and 128
475 (16xMIC), 256 (32xMIC), 512 (64xMIC) mg/L were used for FB-14; FOS, fosfomycin, 512 mg/L
476 were used. *: DAP512+FOS512 vs DAP64+FOS512, P<0.05; **: DAP512+FOS512 vs
477 DAP128+FOS512, P<0.05.

478
479
480
481
482
483
484
485
486
487

488

489

490



491

492 **Figure. 4 Antimicrobial agents killed the adherent cells in the mature biofilms of FB-1 (A),**

493 **FB-2 (B), FB-14 (C), and FB-80 (D).** The adherent cells in the mature biofilms of *E. faecalis* was

494 determined by the CFU numbers. DAP, daptomycin; RIF, rifampin; FOS, fosfomycin. All the

495 three agents were used at 16xMIC. *: DAP vs Control, P<0.05; **: DAP+FOS vs DAP or FOS

496 alone, P<0.05.

497

498

499

500

501


502

503

504

505

506



507

508 **Figure. 5 Daptomycin combined with fosfomycin killed the adherent cells in the mature**
509 **biofilms of FB-1 (A), FB-2 (B), FB-14 (C), and FB-80 (D).** DAP, daptomycin, 64 (16xMIC),
510 128 (32xMIC), 256 (64xMIC), 512 (128xMIC) mg/L were used for FB-1, FB-2, FB-80, and 128
511 (16xMIC), 256 (32xMIC), 512 (64xMIC) mg/L were used for FB-14; FOS, fosfomycin, 512 mg/L
512 were used. *: DAP512+FOS512 vs DAP64+FOS512, $P < 0.05$; **: DAP512+FOS512 vs
513 DAP128+FOS512, $P < 0.05$.

514

515

516

517

518


519

520

521


522

523



524 **Figure. 6 Effects of daptomycin and fosfomycin on the adherent cells in the mature biofilms**
 525 **of FB-1 by confocal laser scanning microscope (CLSM).** The mature biofilms were stained with
 526 SYTO9 and propidium iodide (PI) and observed under a Leica TCS SP8 CLSM. Images were
 527 analyzed by IMARIS 7.0.0 software. Cells stained with green fluorescence were viable and with
 528 red fluorescence were dead. The fluorescence quantities of biofilm were determined by
 529 Leica LAS AF Lite 4.0 software. Data represent mean±SD of three independent experiments.
 530 DAP, daptomycin, 64 (16xMIC), 512 (128xMIC) mg/L were used; FOS, fosfomycin, 512 mg/L
 531 were used. *: DAP64 vs Control, P<0.05; **: DAP64+FOS512 vs DAP64 or FOS512 alone,
 532 P<0.05; ***: DAP512+FOS512 vs DAP64+FOS512, P<0.05.

533
 534
 535
 536
 537
 538
 539
 540
 541
 542
 543
 544
 545
 546
 547



Control

DAP64

FOS512

DAP64+FOS512

DAP512+FOS512

Antimicrobials	SYTO9	PI	PI/Total
Control	49.41±5.38	5.10±2.47	9.4%
DAP64	65.70±7.83	22.79±3.29	25.8%*
FOS512	56.46±4.62	10.42±3.58	15.6%
DAP64+FOS512	16.26±3.17	14.97±3.94	47.9%**
DAP512+FOS512	6.45±2.85	37.53±4.36	85.3%***

548 **Figure. 7 Effects of daptomycin and fosfomycin on the adherent cells in the mature biofilms**
 549 **of FB-2 by confocal laser scanning microscope (CLSM).** The mature biofilms were stained with
 550 SYTO9 and propidium iodide (PI) and observed under a Leica TCS SP8 CLSM. Images were
 551 analyzed by IMARIS 7.0.0 software. Cells stained with green fluorescence were viable and with
 552 red fluorescence were dead. The fluorescence quantities of biofilm were determined by
 553 Leica LAS AF Lite 4.0 software. Data represent mean±SD of three independent experiments.
 554 DAP, daptomycin, 64 (16xMIC), 512 (128xMIC) mg/L were used; FOS, fosfomycin, 512 mg/L
 555 were used. *: DAP64 vs Control, P<0.05; **: DAP64+FOS512 vs DAP64 or FOS512 alone,
 556 P<0.05; ***: DAP512+FOS512 vs DAP64+FOS512, P<0.05.

557

558

559

560

561

562

563

564

565


566

567

568

569

570



Control

DAP128

FOS512

DAP128+FOS512

DAP512+FOS512

Antimicrobials	SYTO9	PI	PI/Total
Control	82.29±5.58	15.37±3.84	15.7%
DAP128	66.20±4.92	29.73±4.84	31.0%*
FOS512	74.58±5.43	18.92±3.67	20.2%
DAP128+FOS512	64.65±6.38	55.36±5.75	46.1%**
DAP512+FOS512	32.34±4.61	76.37±7.26	70.3%***

571 **Figure. 8 Effects of daptomycin and fosfomycin on the adherent cells in the mature biofilms**
 572 **of FB-14 by confocal laser scanning microscope (CLSM).** The mature biofilms were stained
 573 with SYTO9 and propidium iodide (PI) and observed under a Leica TCS SP8 CLSM. Images were
 574 analyzed by IMARIS 7.0.0 software. Cells stained with green fluorescence were viable and with
 575 red fluorescence were dead. The fluorescence quantities of biofilm were determined by
 576 Leica LAS AF Lite 4.0 software. Data represent mean±SD of three independent experiments.
 577 DAP, daptomycin, 128 (16xMIC), 512 (64xMIC) mg/L were used; FOS, fosfomycin, 512 mg/L
 578 were used. *: DAP128 vs Control, P<0.05; **: DAP128+FOS512 vs DAP128 or FOS512 alone,
 579 P<0.05; ***: DAP512+FOS512 vs DAP128+FOS512, P<0.05.

580

581

582

583

584

585

586

587

588


589

590

591

592

593



	Control	DAP64	FOS512	DAP64+FOS512	DAP512+FOS512
Antimicrobials	SYTO9	PI	PI/Total		
Control	93.71±6.26	9.71±2.14	9.4%		
DAP64	79.99±5.86	25.59±3.46	24.2%*		
FOS512	82.65±6.02	15.76±3.25	16.0%		
DAP64+FOS512	60.08±4.54	57.66±5.38	49.0%**		
DAP512+FOS512	7.90±2.36	31.85±4.62	80.1%***		

594 **Figure. 9 Effects of daptomycin and fosfomycin on the adherent cells in the mature biofilms**
 595 **of FB-80 by confocal laser scanning microscope (CLSM).** The mature biofilms were stained
 596 with SYTO9 and propidium iodide (PI) and observed under a Leica TCS SP8 CLSM. Images were
 597 analyzed by IMARIS 7.0.0 software. Cells stained with green fluorescence were viable and with
 598 red fluorescence were dead. The fluorescence quantities of biofilm were determined by
 599 Leica LAS AF Lite 4.0 software. Data represent mean±SD of three independent experiments.
 600 DAP, daptomycin, 64 (16xMIC), 512 (128xMIC) mg/L were used; FOS, fosfomycin, 512 mg/L
 601 were used. *: DAP64 vs Control, P<0.05; **: DAP64+FOS512 vs DAP64 or FOS512 alone,
 602 P<0.05; ***: DAP512+FOS512 vs DAP64+FOS512, P<0.05.
 603